Trial Profile
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2019
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Ropidoxuridine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions
- 31 May 2019 Results assessing safety and efficacy of nimotuzumab and IMRT in patients with nasophyaryngeal carcinoma, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 01 Feb 2017 New trial record